Our hosting provider will be performing UPS maintenance on Tuesday, Oct 25, 2016 between 8 AM and 5 PM PDT. SciCrunch searching services will be down during this time.

Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.


BACKGROUND: Tumor initiation has been attributed to haploinsufficiency at a single locus for a large number of cancers. Patched1 (Ptc1) was one of the first such loci, and Ptc1 haploinsufficiency has been asserted to lead to medulloblastoma and rhabdomyosarcoma in mice. PROCEDURE: To study the role of Ptc1 in cerebellar tumor development and to create a preclinical therapeutic platform, we have generated a conditional Ptc1 haploinsufficiency model of medulloblastoma by inactivating Ptc1 in Pax7-expressing cells of the cerebellum. RESULTS: These mice developed exclusively medulloblastoma. We show that despite the presence of transcription of Ptc1, Ptc1 protein is nearly undetectable or absent in tumors. Our results suggest that Ptc1 loss of function is complete, but achieved at the protein level rather than by the classic genetic two-hit mechanism or a strict half-dosage genetic haploinsufficiency mechanism. Furthermore, we found that bortezomib, a 26S proteasome inhibitor, had a significant anti-tumor activity in vitro and in vivo, which was accompanied by restoration of Ptc1 protein and downregulation of the hedgehog signaling pathway. The same effect was seen for both human and mouse medulloblastoma tumor cell growth. CONCLUSIONS: These results suggest that proteasome inhibition is a potential new therapeutic approach in medulloblastoma.

Pubmed ID: 19213072


  • Taniguchi E
  • Cho MJ
  • Arenkiel BR
  • Hansen MS
  • Rivera OJ
  • McCleish AT
  • Qualman SJ
  • Guttridge DC
  • Scott MP
  • Capecchi MR
  • Keller C


Pediatric blood & cancer

Publication Data

August 15, 2009

Associated Grants

  • Agency: NINDS NIH HHS, Id: K99 NS064171
  • Agency: NINDS NIH HHS, Id: K99 NS064171-01
  • Agency: NCI NIH HHS, Id: P30 CA042014-16
  • Agency: NCI NIH HHS, Id: P30CA54174
  • Agency: Howard Hughes Medical Institute, Id:

Mesh Terms

  • Animals
  • Antineoplastic Agents
  • Boronic Acids
  • Cell Line, Tumor
  • Cell Transformation, Neoplastic
  • Cerebellar Neoplasms
  • Disease Models, Animal
  • Gene Knock-In Techniques
  • Hedgehog Proteins
  • Humans
  • Immunoblotting
  • Immunoprecipitation
  • Loss of Heterozygosity
  • Medulloblastoma
  • Mice
  • Mice, Knockout
  • PAX7 Transcription Factor
  • Proteasome Endopeptidase Complex
  • Protein Isoforms
  • Protein Processing, Post-Translational
  • Pyrazines
  • Receptors, Cell Surface